Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

David Wyles

Concepts (252)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
60
2026
768
11.240
 Why?
Hepatitis C, Chronic
32
2025
152
9.010
 Why?
Hepacivirus
49
2026
243
8.370
 Why?
Hepatitis C
30
2026
254
8.160
 Why?
Benzimidazoles
19
2026
190
4.390
 Why?
Drug Resistance, Viral
18
2025
123
3.860
 Why?
Coinfection
15
2020
141
2.860
 Why?
HIV Infections
28
2022
3154
2.750
 Why?
Quinoxalines
8
2026
65
2.390
 Why?
Ribavirin
15
2020
80
2.280
 Why?
Sulfonamides
14
2026
581
2.280
 Why?
Sofosbuvir
16
2022
61
2.190
 Why?
Fluorenes
7
2020
46
2.130
 Why?
Liver Cirrhosis
8
2020
288
2.080
 Why?
Viral Nonstructural Proteins
10
2025
67
2.080
 Why?
Drug Therapy, Combination
26
2020
1048
1.750
 Why?
Uridine Monophosphate
5
2016
16
1.610
 Why?
Carbamates
9
2020
52
1.390
 Why?
Anti-Retroviral Agents
5
2019
250
1.360
 Why?
Protease Inhibitors
10
2020
102
1.330
 Why?
Pyrrolidines
10
2026
125
1.330
 Why?
Hepatitis B, Chronic
3
2019
22
1.280
 Why?
Proline
12
2026
83
1.260
 Why?
Genotype
21
2025
1835
1.150
 Why?
Sustained Virologic Response
12
2026
46
1.150
 Why?
Congresses as Topic
3
2021
221
1.130
 Why?
Hepatitis, Viral, Human
3
2021
20
1.100
 Why?
Cyclopropanes
12
2026
83
0.990
 Why?
Lactams, Macrocyclic
11
2026
51
0.920
 Why?
Drug Users
2
2024
42
0.920
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
23
0.760
 Why?
HIV-1
8
2020
896
0.740
 Why?
Respiratory Insufficiency
1
2026
326
0.730
 Why?
Treatment Failure
6
2025
365
0.710
 Why?
Virus Replication
7
2012
529
0.700
 Why?
Pyridines
1
2026
605
0.700
 Why?
RNA, Viral
10
2026
688
0.670
 Why?
Disease Eradication
1
2020
5
0.670
 Why?
Organophosphonates
4
2011
97
0.650
 Why?
Humans
79
2026
144957
0.650
 Why?
Homosexuality, Male
2
2021
222
0.620
 Why?
Valine
7
2020
80
0.600
 Why?
Anti-HIV Agents
6
2020
888
0.580
 Why?
Treatment Outcome
20
2026
11695
0.560
 Why?
Aminoisobutyric Acids
6
2026
9
0.550
 Why?
Middle Aged
34
2026
35928
0.550
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.530
 Why?
Leucine
6
2026
116
0.520
 Why?
Ritonavir
6
2020
75
0.510
 Why?
Imidazoles
2
2015
254
0.510
 Why?
Darunavir
1
2017
20
0.510
 Why?
Male
43
2026
72406
0.500
 Why?
Adult
33
2026
40506
0.480
 Why?
Uracil
5
2020
36
0.480
 Why?
Antiretroviral Therapy, Highly Active
3
2015
278
0.470
 Why?
Anilides
5
2020
84
0.460
 Why?
Education, Medical, Continuing
1
2016
132
0.450
 Why?
Female
41
2026
78376
0.450
 Why?
Biomedical Research
1
2021
710
0.430
 Why?
Oligopeptides
2
2013
269
0.420
 Why?
Pyridazines
1
2014
57
0.410
 Why?
Adenine
4
2020
339
0.410
 Why?
2-Naphthylamine
5
2020
6
0.400
 Why?
Viral Load
7
2020
526
0.400
 Why?
Macrocyclic Compounds
3
2019
15
0.400
 Why?
Purines
1
2014
187
0.380
 Why?
Aged
18
2026
25947
0.380
 Why?
Quinolines
1
2014
193
0.380
 Why?
Replicon
3
2009
15
0.380
 Why?
Liver
1
2021
1888
0.370
 Why?
Scavenger Receptors, Class B
1
2012
14
0.360
 Why?
Disease Management
1
2016
647
0.360
 Why?
Mass Screening
4
2025
1348
0.320
 Why?
Retreatment
2
2021
77
0.320
 Why?
Drug Synergism
3
2008
357
0.310
 Why?
Acquired Immunodeficiency Syndrome
2
2020
235
0.280
 Why?
Dideoxynucleosides
2
2005
24
0.280
 Why?
Liver Diseases
2
2016
304
0.270
 Why?
Interferon-alpha
4
2013
197
0.270
 Why?
Nucleoside-Triphosphatase
3
2017
14
0.270
 Why?
Cytokines
1
2015
2065
0.260
 Why?
DEAD-box RNA Helicases
3
2017
90
0.250
 Why?
Serine Endopeptidases
3
2017
128
0.250
 Why?
Amino Acid Substitution
2
2018
304
0.250
 Why?
Cytosine
2
2009
51
0.250
 Why?
Indolizines
1
2026
13
0.240
 Why?
Global Health
2
2020
401
0.240
 Why?
Hospitalization
3
2026
2434
0.240
 Why?
Hepatitis B virus
2
2019
33
0.220
 Why?
HIV
2
2019
250
0.220
 Why?
Double-Blind Method
3
2026
2029
0.220
 Why?
Hepatitis
1
2004
43
0.210
 Why?
Herpes Simplex
1
2005
98
0.210
 Why?
Alanine
2
2021
171
0.200
 Why?
Interferons
2
2015
188
0.190
 Why?
Prevalence
3
2019
2836
0.190
 Why?
Mutation, Missense
3
2014
340
0.180
 Why?
Pyrazoles
1
2026
510
0.180
 Why?
Hospitals
2
2024
732
0.180
 Why?
Interferon beta-1a
1
2021
14
0.180
 Why?
Young Adult
10
2019
14126
0.170
 Why?
Hepatitis A
1
2021
25
0.170
 Why?
Adenosine Monophosphate
1
2021
86
0.170
 Why?
Phylogeny
1
2025
1019
0.160
 Why?
Feasibility Studies
1
2025
1095
0.160
 Why?
Tenofovir
2
2020
295
0.160
 Why?
Hepatitis B
1
2021
66
0.160
 Why?
World Health Organization
1
2020
105
0.160
 Why?
Benzopyrans
2
2017
30
0.160
 Why?
Disease Progression
2
2019
2852
0.150
 Why?
Data Interpretation, Statistical
2
2018
372
0.150
 Why?
Drug Combinations
4
2026
392
0.150
 Why?
Polyethylene Glycols
2
2015
655
0.150
 Why?
Esters
2
2009
78
0.140
 Why?
CD4 Lymphocyte Count
2
2017
277
0.140
 Why?
Ribosomes
2
2010
191
0.140
 Why?
United States
10
2025
15988
0.140
 Why?
Immunologic Factors
1
2020
255
0.140
 Why?
Emergency Service, Hospital
3
2025
2313
0.140
 Why?
Nucleic Acid Conformation
4
2014
726
0.130
 Why?
Alanine Transaminase
1
2018
151
0.130
 Why?
DNA, Viral
1
2019
358
0.130
 Why?
Genes, Viral
1
2016
90
0.120
 Why?
DNA Mutational Analysis
1
2018
409
0.120
 Why?
Molecular Structure
2
2008
501
0.120
 Why?
High-Throughput Nucleotide Sequencing
2
2016
550
0.120
 Why?
Mutation
2
2018
4099
0.120
 Why?
Patient Compliance
1
2020
589
0.120
 Why?
Survival Analysis
1
2019
1385
0.120
 Why?
Dose-Response Relationship, Drug
2
2017
2032
0.110
 Why?
Adolescent
5
2022
22453
0.110
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
18
0.110
 Why?
AIDS-Related Opportunistic Infections
1
2015
130
0.110
 Why?
Chemokines
1
2015
218
0.110
 Why?
Chemokine CXCL10
1
2014
39
0.100
 Why?
Risk Assessment
2
2025
3676
0.100
 Why?
Drug Interactions
1
2015
401
0.100
 Why?
Phenylenediamines
1
2013
12
0.100
 Why?
Fibrosis
1
2016
548
0.100
 Why?
Opiate Substitution Treatment
1
2016
187
0.100
 Why?
Viral Proteins
2
2014
355
0.100
 Why?
Prospective Studies
5
2025
7997
0.100
 Why?
Microbial Sensitivity Tests
2
2012
371
0.100
 Why?
Prognosis
2
2019
4293
0.090
 Why?
Equivalence Trials as Topic
2
2023
36
0.090
 Why?
Quality of Life
1
2025
3192
0.090
 Why?
Drug Discovery
1
2013
155
0.090
 Why?
Administration, Oral
1
2014
848
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
257
0.080
 Why?
Case-Control Studies
2
2017
3608
0.080
 Why?
Cohort Studies
5
2024
5965
0.080
 Why?
Models, Molecular
3
2012
1619
0.080
 Why?
Prodrugs
1
2011
52
0.080
 Why?
Mental Disorders
1
2020
1172
0.080
 Why?
Nucleosides
1
2010
25
0.080
 Why?
Riboswitch
1
2012
63
0.080
 Why?
Telemedicine
1
2020
948
0.080
 Why?
Japan
2
2021
143
0.080
 Why?
Drug Administration Schedule
3
2017
783
0.080
 Why?
Cell Line, Tumor
2
2008
3550
0.070
 Why?
Drug Design
1
2010
173
0.070
 Why?
Biomarkers
1
2020
4275
0.070
 Why?
Cell Line
2
2012
2882
0.070
 Why?
Randomized Controlled Trials as Topic
3
2023
1721
0.070
 Why?
Piperidines
1
2010
217
0.070
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Practice Guidelines as Topic
1
2016
1563
0.070
 Why?
Body Mass Index
1
2017
2438
0.070
 Why?
Immunity, Innate
1
2014
846
0.070
 Why?
Plasmids
1
2009
379
0.070
 Why?
Structure-Activity Relationship
1
2009
570
0.070
 Why?
Inhibitory Concentration 50
1
2006
91
0.060
 Why?
Luciferases
1
2006
152
0.060
 Why?
Genes, Reporter
1
2006
276
0.060
 Why?
Thailand
1
2025
18
0.060
 Why?
Saquinavir
1
2004
1
0.060
 Why?
Simplexvirus
1
2005
82
0.060
 Why?
Indinavir
1
2004
7
0.060
 Why?
Drug Labeling
1
2005
37
0.060
 Why?
Nelfinavir
1
2004
8
0.060
 Why?
Nevirapine
1
2004
18
0.050
 Why?
Uganda
1
2025
93
0.050
 Why?
Benzoxazines
1
2004
31
0.050
 Why?
Oxazines
1
2004
37
0.050
 Why?
Lopinavir
1
2004
30
0.050
 Why?
Pandemics
2
2024
1695
0.050
 Why?
Brazil
1
2025
180
0.050
 Why?
Zidovudine
1
2004
77
0.050
 Why?
Liver Function Tests
1
2004
106
0.050
 Why?
Alkynes
1
2004
66
0.050
 Why?
Reverse Transcriptase Inhibitors
1
2004
87
0.050
 Why?
Transfection
1
2006
940
0.050
 Why?
Time Factors
1
2015
7183
0.050
 Why?
Bone Marrow Transplantation
1
2005
294
0.050
 Why?
Pregnancy
1
2017
7191
0.050
 Why?
Pyrimidinones
1
2004
126
0.050
 Why?
South Africa
1
2025
261
0.050
 Why?
Recombinant Fusion Proteins
1
2006
675
0.050
 Why?
Carcinoma, Hepatocellular
1
2006
372
0.050
 Why?
Polyphosphates
1
2022
45
0.050
 Why?
Singapore
1
2021
27
0.040
 Why?
Republic of Korea
1
2021
42
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2022
133
0.040
 Why?
Dried Blood Spot Testing
1
2022
126
0.040
 Why?
Mexico
1
2021
233
0.040
 Why?
Retrospective Studies
5
2019
17101
0.040
 Why?
Multicenter Studies as Topic
1
2022
405
0.040
 Why?
Protein Biosynthesis
2
2014
458
0.040
 Why?
Liver Neoplasms
1
2006
783
0.040
 Why?
Raltegravir Potassium
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
77
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
117
0.040
 Why?
Intensive Care Units
1
2024
916
0.030
 Why?
Drug Resistance, Multiple, Viral
1
2017
10
0.030
 Why?
Kinetics
1
2020
1629
0.030
 Why?
Longitudinal Studies
1
2024
2947
0.030
 Why?
Oxygen
1
2021
995
0.030
 Why?
Medicaid
1
2020
462
0.030
 Why?
Program Evaluation
1
2020
949
0.030
 Why?
Incidence
2
2013
2883
0.030
 Why?
RNA
1
2022
940
0.030
 Why?
Cell-Free System
1
2014
53
0.030
 Why?
Hepatitis C Antibodies
1
2014
11
0.030
 Why?
Spain
1
2014
48
0.030
 Why?
Polymorphism, Genetic
1
2017
612
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
851
0.030
 Why?
Withholding Treatment
1
2013
81
0.020
 Why?
Patient Care
1
2014
118
0.020
 Why?
Patient Acceptance of Health Care
1
2020
886
0.020
 Why?
Risk Factors
2
2020
10792
0.020
 Why?
Early Diagnosis
1
2014
249
0.020
 Why?
Aged, 80 and over
2
2019
8279
0.020
 Why?
Patient Reported Outcome Measures
1
2017
489
0.020
 Why?
Plasma
1
2014
225
0.020
 Why?
Fluorescence Resonance Energy Transfer
1
2012
178
0.020
 Why?
Virus Internalization
1
2010
65
0.020
 Why?
Ligands
1
2012
674
0.020
 Why?
Recombinant Proteins
1
2013
1371
0.020
 Why?
Magnesium
1
2009
155
0.020
 Why?
Lamivudine
1
2009
65
0.020
 Why?
Pilot Projects
1
2015
1890
0.020
 Why?
Referral and Consultation
1
2014
853
0.020
 Why?
Logistic Models
1
2013
2119
0.020
 Why?
Genome, Viral
1
2009
218
0.020
 Why?
Phenotype
1
2014
3164
0.010
 Why?
Base Sequence
1
2009
2191
0.010
 Why?
Severity of Illness Index
1
2013
2925
0.010
 Why?
Mice, Transgenic
1
2009
2185
0.010
 Why?
Animals
2
2018
38109
0.010
 Why?
Substance-Related Disorders
1
2011
1094
0.010
 Why?
Signal Transduction
1
2009
5233
0.010
 Why?
Mice
1
2009
18365
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (252) concept(s)
_
Co-Authors Expand Description
See all (20) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)